📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Pheast

1.1 - Company Overview

Pheast Logo

Pheast

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of checkpoint therapies to harness the innate immune system, including PHST001, an anti-CD24 antibody that blocks a key macrophage ‘don’t eat me’ signal on cancer cells to induce an anti-cancer immune response, and a proprietary discovery platform that uncovers tumor-specific ‘don’t eat me’ signals to create novel macrophage-targeted immunotherapies.

Products and services

  • Proprietary Discovery Platform: Proprietary system that uncovers 'don’t eat me' signals in different cancers to create novel, tumor-specific, macrophage-targeted immunotherapies
  • PHST001: Antibody-based anti-CD24 drug candidate that blocks a key macrophage 'don’t eat me' signal on cancer cells, inducing anti-cancer immune responses and showing therapeutic efficacy in preclinical models
  • Checkpoint Therapies Development: Innate-immunity-focused programs that develop checkpoint therapies to harness the innate immune system for anti-cancer benefit

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Pheast

ImmuneXcite Logo

ImmuneXcite

HQ: United States Website
  • Description: Provider of a platform technology for enhancing the efficacy of therapeutic monoclonal antibodies for disease targets.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full ImmuneXcite company profile →
Proclara Biosciences Logo

Proclara Biosciences

HQ: United States Website
  • Description: Provider of a pioneering new approach to treating neurodegenerative diseases.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Proclara Biosciences company profile →
Osivax Logo

Osivax

HQ: France Website
  • Description: Provider of immunotherapy vaccines powered by the oligoDOM self-assembling nanoparticle platform to elicit potent T- and B-cell responses and enable universal vaccines against mutating pathogens. Pipeline includes OVX836, a universal influenza A vaccine targeting nucleoprotein; OVX033, a universal sarbecovirus vaccine targeting nucleocapsid; and PANHPVAX, a pan-strain HPV vaccine.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Osivax company profile →
GT Biopharma Logo

GT Biopharma

HQ: United States Website
  • Description: Provider of TriKE immunotherapy technology that bridges natural killer cells to cancer cells to boost anti-tumor responses. Pipeline includes GTB-3550 for CD33+ leukemias (AML, high-risk MDS), GTB-3650 using camelid nanobodies for CD33+ leukemias, and GTB-5550, GTB-4550, GTB-6550 for B7H3, PD-L1, and HER2 positive solid tumors.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full GT Biopharma company profile →
Medicago Logo

Medicago

HQ: Canada Website
  • Description: Provider of vaccines in Canada, leveraging proprietary plant-based Proficia and Virus-Like Particles (VLP) technologies; focuses on the research, development, production, and commercialization of vaccines, with product candidates including an H5N1 pandemic candidate.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Medicago company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Pheast

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Pheast

2.2 - Growth funds investing in similar companies to Pheast

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Pheast

4.2 - Public trading comparable groups for Pheast

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Pheast

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Pheast

What does Pheast do?

Pheast is a provider of checkpoint therapies to harness the innate immune system, including PHST001, an anti-CD24 antibody that blocks a key macrophage ‘don’t eat me’ signal on cancer cells to induce an anti-cancer immune response, and a proprietary discovery platform that uncovers tumor-specific ‘don’t eat me’ signals to create novel macrophage-targeted immunotherapies.

Who are Pheast's competitors?

Pheast's competitors and similar companies include ImmuneXcite, Proclara Biosciences, Osivax, GT Biopharma, and Medicago.

Where is Pheast headquartered?

Pheast is headquartered in United States.

How many employees does Pheast have?

Pheast has 1,000 employees 🔒.

When was Pheast founded?

Pheast was founded in 2010 🔒.

What sector and industry vertical is Pheast in?

Pheast is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Pheast

Who are the top strategic acquirers in Pheast's sector and industry

Top strategic M&A buyers and acquirers in Pheast's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Pheast?

Top strategic M&A buyers groups and sectors for Pheast include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Pheast's sector and industry vertical

Which are the top PE firms investing in Pheast's sector and industry vertical?

Top PE firms investing in Pheast's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Pheast's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Pheast's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Pheast's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Pheast include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Pheast's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Pheast?

The key public trading comparables and valuation benchmarks for Pheast include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Pheast for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Pheast with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Pheast's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Pheast with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Pheast's' sector and industry vertical?

Access recent funding rounds and capital raises in Pheast's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Pheast